Abbott (ABT) Receives FDA's Approval for the TriClip TEER System

Abbott Laboratories, Inc. (ABT) recently secured the FDA’s approval for the TriClip transcatheter edge-to-edge repair (TEER) system, which is specifically designed for the treatment of tricuspid regurgitation (TR) or a leaky tricuspid valve. This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstentions, that the benefits of TriClip outweighed the risks.The approval helps address ...